glp 1 and intermittent fasting + GLP-1 Injections: Smart or Dangerous? | Blog You probably shouldn't do intermittent

India is home to over 100 million people with diabetes and approximately 250 million classified as obese or overweight.[15] What makes the situation uniquely dangerous is the Thin-Fat Indian paradox: South Asians tend to accumulate more visceral (belly) fat, liver fat, and less lean muscle mass at lower body weights than Western populations.[8][9][10] While GLP-1 medications are a global phenomenon, they are particularly critical for the Thin-Fat Indian phenotype

These figures represent a significant improvement over many previous weight loss interventions

Many patients find success by starting with lifestyle changes for several weeks before adding medication, or by beginning both simultaneously under medical guidance

Risk: Novo has been steadily losing ground to Mounjaro and Zepbound, and Jim Cramer recently noted Lillys pipeline could deliver the unassailable knockout punch against Novo Nordisk because its got fat busting without muscle crunch. A value trap is the obvious failure mode

[DOI] [PMC free article] [PubMed] [Google Scholar] 445.Noyan-Ashraf, M

K., et al